Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunfeng Ni

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Translational Lung Cancer Research|December 10, 2025
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort studyYizhang Li, Jialing Jiang, Xin Yao, et al.
The Analyst|December 5, 2013
Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinomaLei Wang, Zhipei Zhang, Lijun Huang, et al.
Thoracic Cancer|August 4, 2024
Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancerTian Zhang, Yajuan Zhang, Yunfeng Ni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2022
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogramXiaohui Jia, Xiangling Chu, Lili Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2022
Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84]Xiaohui Jia, Xiangling Chu, Lili Jiang, et al.
International Journal of Surgery (London, England)|March 7, 2025
Clinical outcomes and short-term survival of neoadjuvant immunochemotherapy for resectable esophageal cancer: a multicenter retrospective cohort studyKe Lan, Xiaolong Yan, Jie Lei, et al.
International Journal of Surgery (London, England)|May 20, 2022
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)Xiaolong Yan, Hongtao Duan, Yunfeng Ni, et al.
JAMA Oncology|August 3, 2023
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical TrialJie Lei, Jinbo Zhao, Li Gong, et al.
The Journal of Clinical Investigation|February 25, 2025
A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancerRuixiang Zhang, Yongzhan Nie, Xiaobing Chen, et al.
British Journal of Cancer|August 7, 2025
Physiological and psychological symptom management based on electronic patient-reported outcomes: the TD-WELLBEING randomized clinical trialPengyu Jing, Ying Liang, Zhijun Tan, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Translational Lung Cancer Research|December 10, 2025
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort studyYizhang Li, Jialing Jiang, Xin Yao, et al.
The Analyst|December 5, 2013
Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinomaLei Wang, Zhipei Zhang, Lijun Huang, et al.
Thoracic Cancer|August 4, 2024
Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancerTian Zhang, Yajuan Zhang, Yunfeng Ni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2022
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogramXiaohui Jia, Xiangling Chu, Lili Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2022
Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84]Xiaohui Jia, Xiangling Chu, Lili Jiang, et al.
International Journal of Surgery (London, England)|March 7, 2025
Clinical outcomes and short-term survival of neoadjuvant immunochemotherapy for resectable esophageal cancer: a multicenter retrospective cohort studyKe Lan, Xiaolong Yan, Jie Lei, et al.
International Journal of Surgery (London, England)|May 20, 2022
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)Xiaolong Yan, Hongtao Duan, Yunfeng Ni, et al.
JAMA Oncology|August 3, 2023
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical TrialJie Lei, Jinbo Zhao, Li Gong, et al.
The Journal of Clinical Investigation|February 25, 2025
A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancerRuixiang Zhang, Yongzhan Nie, Xiaobing Chen, et al.
British Journal of Cancer|August 7, 2025
Physiological and psychological symptom management based on electronic patient-reported outcomes: the TD-WELLBEING randomized clinical trialPengyu Jing, Ying Liang, Zhijun Tan, et al.
Pageof 6